CAJ | 학술논문

目的：评价特拉唑嗪治疗良性前列腺增生( BPH)合并原发性高血压患者的有效性、安全性及依从性。方法选择200例BPH合并原发性高血压患者作为研究对象,将其随机分为观察组和对照组,每组100例。对照组患者给予常规降压药物治疗,观察组患者在对照组的基础上加用口服特拉唑嗪,随访3个月。治疗前、治疗第1个月末、治疗第3个月末,记录两组患者的国际前列腺症状评分( IPSS)变化值、血压、最大尿流率( Qmax)的变化及不良反应发生情况。结果治疗第3个月末,两组患者的收缩压和舒张压均较治疗前显著下降(P<0．05),且观察组改善幅度大于对照组(P<0．05)；治疗第1个月末、第3个月末,两组患者的IPSS下降(P<0．05),Qmax上升(P<0．05),且观察组改善幅度大于对照组(P<0．05)；对照组出现头晕6例,心悸3例,恶心3例,其他不良反应6例；观察组出现头晕6例,心悸3例,恶心2例,其他不良反应7例,两组比较差异无统计学意义( P>0．05)。结论特拉唑嗪治疗BPH合并高血压可有效改善患者的下尿路症状,明显提高患者的生活质量,并可辅助控制血压,具有良好的安全性和依从性。
목적：평개특랍서진치료량성전렬선증생( BPH)합병원발성고혈압환자적유효성、안전성급의종성。방법선택200례BPH합병원발성고혈압환자작위연구대상,장기수궤분위관찰조화대조조,매조100례。대조조환자급여상규강압약물치료,관찰조환자재대조조적기출상가용구복특랍서진,수방3개월。치료전、치료제1개월말、치료제3개월말,기록량조환자적국제전렬선증상평분( IPSS)변화치、혈압、최대뇨류솔( Qmax)적변화급불량반응발생정황。결과치료제3개월말,량조환자적수축압화서장압균교치료전현저하강(P<0．05),차관찰조개선폭도대우대조조(P<0．05)；치료제1개월말、제3개월말,량조환자적IPSS하강(P<0．05),Qmax상승(P<0．05),차관찰조개선폭도대우대조조(P<0．05)；대조조출현두훈6례,심계3례,악심3례,기타불량반응6례；관찰조출현두훈6례,심계3례,악심2례,기타불량반응7례,량조비교차이무통계학의의( P>0．05)。결론특랍서진치료BPH합병고혈압가유효개선환자적하뇨로증상,명현제고환자적생활질량,병가보조공제혈압,구유량호적안전성화의종성。
Objective To observe and evaluate the efficacy,safety and compliance of terazosin in the treat-ment of the patients with benign prostatic hyperplasia ( BPH) complicated with hypertension. Methods 200 cases of patients with BPH complicated with hypertension were selected and randomly divided into observation group and con-trol group,100 cases in each group. Patients in control group were treated with normal antihypertensive drug,while the patients in observation group were added oral administration of terazosin on the basis of the therapy of control group. The patients were followed up for 3 months. The changes of international prostate symptom score ( IPSS) ,blood pres-sure,maximal urinary flow rate (Qmax)and the adverse reactions before the treatment,at the end of the 1st,3rd month of treatment were observed and recorded. Results At the end of the 3rd month of treatment,the systolic and diastolic blood pressures of the patients in the two groups were significantly lower (P<0. 05),and the improvement of observa-tion group was significantly obvious than that of control group (P<0. 05);at the end of the 1st and the 3rd month of treatment,IPSS of the two groups decreased significantly (P<0. 05),and Qmax increased significantly (P<0. 05), and the improvement of observation group was significantly than that of control group (P<0. 05). There were 6 cases of dizziness,3 cases of palpitation,3 cases of nausea and 6 cases of other adverse reactions in control group,and 6 cases of dizziness,3 cases of palpitation,2 cases of nausea and 7 cases of other adverse reactions in observation group. There was no significant difference between the two groups ( P >0. 05 ) . Conclusion Terazosin in the treatment of BPH complicated with hypertension can improve the lower urinary tract symptoms and the life quality of the patients. It can help control the blood pressure of the patients with good safety and compliance,it is worthy of clinical application.